QPPV.COM KNOWLEDGE ASSESSMENT

Signal Evaluation: Fluoroquinolones and Tendon Injury and Tendon Rupture

Test your understanding of the concepts covered by Signal Evaluation: Fluoroquinolones and Tendon Injury and Tendon Rupture.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What was the principal limitation of the early case reports linking quinolones or fluoroquinolones with tendon injury?

They could not identify the anatomical site of injury They could establish population incidence but not causality They could suggest an unusual association but could not establish incidence or reliably exclude coincidence They were unsuitable for identifying rare adverse events

Question 2 of 10 A patient develops Achilles tendon pain five days after starting a fluoroquinolone. Which interpretation is most appropriate?

The timing is incompatible because tendon injury requires prolonged cumulative exposure The timing is compatible with the known signal, although it does not by itself prove causality The timing proves that the fluoroquinolone caused the event The timing is relevant only if the patient had already stopped treatment

Question 3 of 10 A clinician is considering a fluoroquinolone for a severe infection with resistance to suitable alternatives in an older patient receiving corticosteroids. What is the most appropriate professional interpretation?

The drug is automatically contraindicated because any risk factor rules out treatment The risk factors are irrelevant because the infection is severe The higher susceptibility should be explicitly weighed against the clinical need and lack of effective alternatives The clinician should use the drug only if a tendon rupture has already occurred

Question 4 of 10 What is the most appropriate ongoing pharmacovigilance objective after regulatory restrictions and warnings have been implemented?

Stop surveillance because the signal is already established Determine whether new cases are causal without considering prescribing patterns Assess whether risk-minimisation measures are effective and whether new patterns or populations emerge Use spontaneous-report counts alone to calculate absolute incidence

Question 5 of 10 Why is absence of immediate improvement after fluoroquinolone discontinuation not strong evidence against causality in a tendon-injury case?

Tendon injury is structural, so stopping exposure cannot immediately restore tissue integrity Dechallenge is always irrelevant in pharmacovigilance Fluoroquinolones cannot be discontinued once treatment begins Only laboratory abnormalities can show a dechallenge response

Question 6 of 10 Which patient profile represents the highest susceptibility pattern described in the article?

A young adult with normal renal function and no corticosteroid exposure An older patient receiving systemic corticosteroids with renal impairment A middle-aged patient with an uncomplicated short course and no tendon history A healthy adolescent with no concomitant medication

Question 7 of 10 Why should a tendon event occurring months after fluoroquinolone discontinuation still be considered during case assessment?

The drug remains pharmacologically active indefinitely in every patient Delayed tendon injury has been recognized, and structural injury may manifest after exposure has ended Any event occurring after treatment is automatically drug-related Delayed events are more specific for fluoroquinolones than events during treatment

Question 8 of 10 Why can a very large spontaneous-reporting ROR occur without representing an equivalent increase in clinical risk?

ROR calculations use no adverse-event information Disproportionality is influenced by reporting behavior, notoriety, indication, co-medications and lack of an exposure denominator ROR is always lower than relative risk Spontaneous-report databases contain only confirmed causal cases

Question 9 of 10 Which evidence combination most strongly supports moving the signal beyond a hypothesis generated by spontaneous reports?

A single laboratory experiment without human data Repeated clinical phenotypes, compatible timing, epidemiological association and consistent risk modification A large ROR interpreted as a direct incidence estimate One case with a positive temporal relationship and no alternative explanation

Question 10 of 10 What supports interpreting tendon injury as a class concern across fluoroquinolones?

Class membership alone, without clinical evidence Evidence of similar clinical reactions across multiple fluoroquinolones together with pharmacological and regulatory assessment The assumption that all medicines in a class have identical toxicity A single report involving an unspecified quinolone

Signal Evaluation: Fluoroquinolones and Tendon Injury and Tendon Rupture

Cookie Settings